StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

Earnings

Vanda Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 10, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$69.80M
+24.1% on a year earlier
EPS, Q3 FY2026
-$0.37
-$0.38 a year earlier
Latest guidance
Issued
Oct 28, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Vanda Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 10, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026after the close$69.80M+24.1%-$0.37Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close$51.70M+3.3%-$0.82Release
Q4 FY2025ended Dec 31, 2025Feb 11, 2026after the close$57.20M+7.5%-$2.39Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025after the close$56.26M+17.9%-$0.38Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025before the open$52.60M+4.2%-$0.46Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close$50.04M+5.3%-$0.50Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025after the close$53.20M+17.4%-$0.08Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$47.70M+22.9%-$0.09Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024after the close$50.50M+9.5%-$0.08Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$47.50M-24.0%-$0.07Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Vanda Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$240.00M–NewOct 28, 2026
Total revenuesFY2026$240.00M – $290.00M$230.00M – $260.00MRaisedMay 6, 2026
Fanapt ® net product salesFY2026$150.00M – $170.00M–NewFeb 11, 2026
Other net product salesFY2026$80.00M – $90.00M–LoweredFeb 11, 2026

Guidance vs results

The last range Vanda Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$210.00M – $230.00M$216.10MΣ4QWithin range

Guidance history

Every forecast Vanda Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026total revenueFY2026$240.00MNew
May 6, 2026Total revenuesFY2026$240.00M – $290.00MRaised
Feb 11, 2026Fanapt ® net product salesFY2026$150.00M – $170.00MNew
Feb 11, 2026Other net product salesFY2026$80.00M – $90.00MLowered
Feb 11, 2026Total revenuesFY2026$230.00M – $260.00MNew
Oct 29, 2025Year-end 2025 CashFY2025$260.00M – $290.00MNew
Oct 29, 2025Total revenuesFY2025$210.00M – $230.00MNew
Jul 31, 2025Year-end 2025 CashFY2025$280.00M – $320.00MReaffirmed
Jul 31, 2025Total revenuesFY2025$210.00M – $250.00MReaffirmed
May 7, 2025Year-end 2025 CashFY2025$280.00M – $320.00MNew
May 7, 2025Total revenuesFY2025$210.00M – $250.00MReaffirmed
Feb 13, 2025Total revenuesFY2025$210.00M – $250.00MNew
Nov 6, 2024Year-end 2024 CashFY2024$370.00M – $390.00MRaised
Nov 6, 2024Total revenuesFY2024$190.00M – $210.00MRaised
Jul 31, 2024Year-end 2024 CashFY2024$360.00M – $390.00MNew
Jul 31, 2024Total revenuesFY2024$180.00M – $210.00MNew
Nov 2, 2022Year-end 2022 CashFY2022$450.00MRaised
Nov 2, 2022Total revenuesFY2022$240.00M – $270.00MLowered
Nov 2, 2022HETLIOZ ® net product salesFY2022$150.00M – $170.00MLowered
Nov 2, 2022Fanapt ® net product salesFY2022$90.00M – $100.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Vanda Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. News
  5. Results
  6. News
  7. News
  8. News
  9. News
  10. Results
  11. News
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?